Format

Send to

Choose Destination
Cancer Immunol Res. 2018 Mar;6(3):255-266. doi: 10.1158/2326-6066.CIR-17-0320. Epub 2018 Jan 30.

YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma.

Author information

1
Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea.
2
Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
3
Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
4
Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea. joonkim@kaist.ac.kr ecshin@kaist.ac.kr park3@kaist.ac.kr.
#
Contributed equally

Abstract

Activation of YAP, a Hippo pathway effector, is an important resistance mechanism to BRAF inhibitor (BRAFi) in melanoma. Emerging evidence also suggests that YAP is involved in suppression of the antitumor immune response. However, the potential direct impact of YAP activity on cytotoxic T-cell immune responses has not been explored yet. Here, we show that BRAFi-resistant melanoma cells evade CD8+ T-cell immune responses in a PD-L1-dependent manner by activating YAP, which synchronously supports melanoma cell survival upon BRAF inhibition. PD-L1 expression is elevated in BRAFi-resistant melanoma cells, in which YAP is robustly activated, and YAP knockdown decreases PD-L1 expression. In addition, constitutively active YAP (YAP-5SA) increases PD-L1 expression by binding to an upstream enhancer of the PD-L1 gene and potentiating its transcription. Both BRAFi-resistant and YAP-5SA-expressing melanoma cells suppress the cytotoxic function and cytokine production of Melan-A-specific CD8+ T cells, whereas anti-PD-1 antibody reverses the YAP-mediated T-cell suppression. Moreover, nuclear enrichment of YAP in clinical melanoma samples correlates with increased PD-L1 expression. Our findings show that YAP directly mediates evasion of cytotoxic T-cell immune responses in BRAFi-resistant melanoma cells by upregulating PD-L1, and targeting of YAP-mediated immune evasion may improve prognosis of melanoma patients. Cancer Immunol Res; 6(3); 255-66. ©2018 AACR.

PMID:
29382670
DOI:
10.1158/2326-6066.CIR-17-0320
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center